Literature DB >> 35277778

Abnormal expression of interleukin-6 is associated with epidermal alternations in localized scleroderma.

Xingyu Zhu1,2, Liuyiqi Jiang1, Qian Zhong1, Xiangzhen Kong1, Rui Zhang1, Lingxian Zhu1, Qingmei Liu3, Wenyu Wu3, Yimei Tan4,5, Jiucun Wang6,7, Jingjing Xia8,9.   

Abstract

OBJECTIVES: Localized scleroderma (LSc) is a disease characterized by the excessive deposition of collagen and thereby thickening of the dermis. In recent years, studies reported that LSc demonstrated compromised skin barrier related to the progression of the disease. However, human studies examining epidermis in scleroderma are still sparse and lack systematic research. This study aims to investigate the structural and functional changes in the LSc epidermis and further explore the underlying mechanisms, providing a new angle to treat LSc in the clinic.
METHODS: A total of 136 skin sites, including lesion and non-lesion control, from 27 LSc patients were analyzed. Ultrasonic testing, trans-epidermal water loss (TEWL), and epidermal hydration were assessed to investigate the structural and functional alternations; correlations between these parameters were analyzed. To explore the underlying mechanism, skin-fibrosis mouse model and cellular model by bleomycin (BLM) were deployed.
RESULTS: The epidermal thickness was markedly increased, with a significant decline of hydration (dryness) in the LSc lesion skin. Epidermal hydration presented a negative correlation with the thickness. TEWL was not altered. The mouse model validated these morphological changes in the epidermis and indicated that interleukin-6 (IL-6) was significantly elevated. Furthermore, cellular study demonstrated that increased phosphorylation of p38 in keratinocyte promoted the secretion of IL-6, stimulating cell proliferation.
CONCLUSION: This study characterized the epidermal alterations in LSc patients, suggesting that keratinocyte-derived abnormal IL-6 secretion can lead to the thickening of the epidermis, promoting dryness. The topical application of moisturizer may largely relieve dryness and related pruritus, thus improve the quality of life in LSc patients. Key Points • Epidermal thickness was increased in LSc lesion skin with declined hydration level. • Skin fibrosis mouse model validated the epidermal alteration in LSc patient. • p38-dependent IL-6 overexpression in keratinocyte result in epidermal thickening.
© 2022. The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR).

Entities:  

Keywords:  Epidermal thickness; Hydration; Interleukin-6 (IL-6); Localized scleroderma (LSc)

Mesh:

Substances:

Year:  2022        PMID: 35277778     DOI: 10.1007/s10067-022-06127-w

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  37 in total

Review 1.  Systemic sclerosis and localized scleroderma--current concepts and novel targets for therapy.

Authors:  Oliver Distler; Antonio Cozzio
Journal:  Semin Immunopathol       Date:  2015-11-17       Impact factor: 9.623

2.  Symmetrical pigmented sclerosis enclosed by pruritic erythema: a new variant of morphoea?

Authors:  H Minato; R Taki; Y Miyachi; A Utani
Journal:  Br J Dermatol       Date:  2009-07-03       Impact factor: 9.302

Review 3.  Tocilizumab: a novel humanized anti-interleukin 6 (IL-6) receptor antibody for the treatment of patients with non-RA systemic, inflammatory rheumatic diseases.

Authors:  Rieke Alten; Tazio Maleitzke
Journal:  Ann Med       Date:  2013-05-08       Impact factor: 4.709

4.  Ultraviolet A1-induced downregulation of human beta-defensins and interleukin-6 and interleukin-8 correlates with clinical improvement in localized scleroderma.

Authors:  A Kreuter; J Hyun; M Skrygan; A Sommer; A Bastian; P Altmeyer; T Gambichler
Journal:  Br J Dermatol       Date:  2006-09       Impact factor: 9.302

Review 5.  Localized scleroderma.

Authors:  Ronald M Laxer; Francesco Zulian
Journal:  Curr Opin Rheumatol       Date:  2006-11       Impact factor: 5.006

6.  Health-related quality of life in morphoea.

Authors:  N K Klimas; A D Shedd; I H Bernstein; H Jacobe
Journal:  Br J Dermatol       Date:  2015-04-08       Impact factor: 9.302

7.  Demonstration of interleukin-2, interleukin-4 and interleukin-6 in sera from patients with localized scleroderma.

Authors:  H Ihn; S Sato; M Fujimoto; K Kikuchi; K Takehara
Journal:  Arch Dermatol Res       Date:  1995       Impact factor: 3.017

Review 8.  Localized scleroderma: clinical spectrum and therapeutic update.

Authors:  Mariana Figueiroa Careta; Ricardo Romiti
Journal:  An Bras Dermatol       Date:  2015 Jan-Feb       Impact factor: 1.896

Review 9.  MicroRNA in localized scleroderma: a review of literature.

Authors:  Katarzyna Wolska-Gawron; Joanna Bartosińska; Dorota Krasowska
Journal:  Arch Dermatol Res       Date:  2019-10-21       Impact factor: 3.017

10.  Periostin in Mature Stage Localized Scleroderma.

Authors:  Min-Woo Kim; Jung Tae Park; Jung Ho Kim; Seong-Joon Koh; Hyun-Sun Yoon; Soyun Cho; Hyun-Sun Park
Journal:  Ann Dermatol       Date:  2017-05-11       Impact factor: 1.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.